Kerry has agreed a strategic licensing partnership with Pharma Food International (PFI) for the development, application and global sales of a joint health ingredient technology for functional foods and beverages and dietary supplements.
The partnership and licensing agreement provides Kerry access to the joint health technology developed by PFI through more than a decade of research. The ingredient promotes the natural production of hyaluronic acid, keeping joints lubricated and mobile and ultimately helping to reduce discomfort and stiffness in knee joints and providing benefit to people with osteoarthritis. The water-soluble ingredient creates opportunities for functional food and beverage applications as well as dietary supplements. The ingredient has been formulated into several products in the Japanese market, and Kerry will be developing a brand positioning for the technology, supporting application and development and supplying the ingredient to customers across the world.
John Quilter, vice-president and general manager for Kerry’s ProActive Health business, commented: “We are delighted to partner with PFI on this new joint health technology which will complement our portfolio of science-backed branded ingredients, including GanedenBC30 probiotic, Wellmune yeast beta glucan, and our most recent addition, Bio-K Plus probiotics.”
Kyoto-headquartered PFI works in the areas of research, development and marketing of functional food ingredients, healthcare products, and biopharmaceutical drugs.
Dr Mukjo Kim, CEO of PFI, concluded: “We are pleased and excited to be working with Kerry. PFI has been researching and developing original materials for the global market and now that we have established a cooperative relationship with Kerry, we will be able to accelerate our global expansion.
“We expect strong synergies between PFI’s research capabilities and Kerry’s global commercial network.”